Loading organizations...
NGM Biopharmaceuticals is a biopharmaceutical company dedicated to discovering and developing novel, life-changing medicines. The company focuses on creating first-in-class therapeutics by translating powerful human biology into important new treatments. Their technical approach involves a multi-step drug discovery and development process, aiming to address significant unmet medical needs across various therapeutic areas with a broad and diverse pipeline.
The company was founded in 2007 by Jin-Long Chen, David Goeddel, and Alex DePaoli. David Goeddel brought substantial prior experience to the venture, having co-founded Tularik, a successful biotechnology company. Jin-Long Chen served as the initial Chief Scientific Officer, leading the scientific direction. The founders shared an insight into leveraging fundamental human biology to create transformative therapeutic interventions.
NGM Biopharmaceuticals targets individuals whose health and lives have been significantly disrupted by disease. Their vision is to deliver life-changing medicines to patients by harnessing the powerful biological mechanisms underlying major diseases. The company remains committed to advancing its pipeline to provide innovative solutions for patients globally, striving to make a lasting impact on human health.
NGM Biopharmaceuticals has raised $335.0M across 6 funding rounds.
Key people at NGM Biopharmaceuticals.
NGM Biopharmaceuticals has raised $335.0M in total across 6 funding rounds.
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company discovering and developing novel therapeutics targeting key biological pathways in liver and metabolic diseases, retinal diseases, oncology, cardio-metabolic conditions, and ophthalmic disorders.[1][2][3] It serves patients with unmet medical needs by leveraging a biology-centric drug discovery approach to advance proprietary drug candidates, several in clinical development, including NGM120—a GDF15/GFRAL antagonist antibody in Phase 2 trials for hyperemesis gravidarum (extreme pregnancy sickness) and cancer cachexia.[2][5] The company demonstrates growth momentum through an expanding pipeline and recent initiation of the EMERALD Phase 2 trial for NGM120, positioning it to address large unmet needs in transformative medicines.[2][5]
Founded in 2007 and headquartered in South San Francisco, California, NGM Biopharmaceuticals emerged as a biotech innovator focused on biology-driven drug discovery.[1] Key leaders include CEO David J. Woodhouse, Ph.D., CSO Dan Kaplan, Ph.D., CMO Hsiao D. Lieu, M.D., President & CFO Siobhan Nolan Mangini, and General Counsel Valerie Pierce, guiding its evolution from early research into a NASDAQ-listed entity (ticker: NGM).[1] Pivotal moments include building a robust pipeline with proof-of-concept studies and clinical advancements, such as the ongoing EMERALD trial, reflecting steady traction in harnessing novel biological insights.[2][5]
NGM rides the wave of precision medicine and biologics innovation, targeting overactivated pathways like GDF15/GFRAL in metabolic and cachexia-related disorders amid rising demand for targeted therapies in oncology, liver disease, and women's health.[2][5] Timing aligns with advances in antibody therapeutics and growing recognition of conditions like hyperemesis gravidarum, fueled by market forces such as aging populations, obesity epidemics, and post-pandemic focus on metabolic health.[1][3] As a NASDAQ-listed player, NGM influences the biotech ecosystem by contributing to pipeline diversity and validating novel targets, potentially accelerating industry-wide adoption of biology-driven platforms.[2]
NGM is poised for milestone readouts from the EMERALD Phase 2 trial of NGM120, which could validate its platform in hyperemesis gravidarum and expand into cancer cachexia, unlocking blockbuster potential in underserved areas.[5] Trends like AI-enhanced discovery, combination therapies, and regulatory emphasis on rare diseases will shape its trajectory, with pipeline growth likely amplifying its influence as a nimble biotech innovator.[2] Returning to its biology-driven roots, NGM's momentum positions it to deliver transformative impact for patients facing disease-disrupted lives.[4][5]
NGM Biopharmaceuticals has raised $335.0M across 6 funding rounds. Most recently, it raised $120.0M Series A in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2024 | $120M Series A | The Column Group | ARCH Venture Partners, Atlas Venture, Foresite Capital | Announced |
| Mar 1, 2015 | $58M Series D | — | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group | Announced |
| Jul 18, 2013 | $50M Series C | — | — | Announced |
| Mar 1, 2010 | $55M Series B | — | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group | Announced |
| Dec 1, 2009 | $27M Series A | — | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group | Announced |
| Feb 12, 2008 | $25M Venture Round | — | — | Announced |
Key people at NGM Biopharmaceuticals.
NGM Biopharmaceuticals has raised $335.0M in total across 6 funding rounds.
NGM Biopharmaceuticals's investors include The Column Group, ARCH Venture Partners, Atlas Venture, Foresite Capital.
